Consistent with its fiduciary duties and in consultation with its financial advisors and legal counsel, Endologix Board of Directors will review and consider the unsolicited proposal and will make a determination and respond in due course. Endologix urges its stockholders to defer judgment on the unsolicited proposal until that determination has been made.
About Endologix
Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix Powerlink System is an endovascular stent graft for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix website at www.endologix.com.
Contact:
Endologix, Inc. John McDermott, President and CEO 949-595-7200 www.endologix.com or Investors: Lippert/Heilshorn & Associates, Inc. Bruce Voss or Jody Cain, 310-691-7100 bvoss@lhai.com jcain@lhai.com www.lhai.com
Source: Endologix, Inc.
